Cholinergic Capsules and Academic Admonitions

Literature Cited

1. 1. 

   Wurster DE, Taylor PW Jr 1965. Dissolution kinetics of certain crystalline forms of prednisolone I and II. J. Pharm. Sci. 54:670–76
   [Google Scholar]
2. 2. 

   Taylor PW Jr, Chidsey CA, Richardson KC, Cooper T, Michaelson IA. 1966. Subcellular distribution of norepinephrine in the normal and surgically denervated cat heart. Biochem. Pharm. 15:681–90
   [Google Scholar]
3. 3. 

   Burgen ASV. 1966. The drug-receptor complex. J. Pharm. Pharmacol. 18:137–49
   [Google Scholar]
4. 4. 

   Taylor PW, King RW, Burgen ASV 1970. Kinetics of complex formation between human carbonic anhydrase and aromatic sulfonamides. Biochemistry 9:2638–45
   [Google Scholar]
5. 5. 

   Taylor PW, Burgen ASV. 1971. Kinetics of carbonic anhydrase-inhibitor complex formation. Comparison of anion- and sulfonamide-binding mechanisms. Biochemistry 10:3859–66
   [Google Scholar]
6. 6. 

   Taylor PW, Feeney JF, Burgen ASV 1971. Investigation of the mechanism of ligand binding with cobalt (II) human carbonic anhydrase by hydrogen-1 and fluorine-19 nuclear magnetic resonance spectroscopy. Biochemistry 10:3866–75
   [Google Scholar]
7. 7. 

   Massoulié J, Anselmet A, Bon S, Krejci E, Legay C et al. 2008. The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization. Chem. Biol. Interact. 119:29–42
   [Google Scholar]
8. 8. 

   Silman I, Futerman AH. 1987. Modes of attachment of acetylcholinesterase to the surface membrane. FEBS J 170:11–22
   [Google Scholar]
9. 9. 

   Lwebuga-Mukasa JS, Lappi S, Taylor P 1976. Molecular forms of acetylcholinesterase from Torpedo californica: their relationship to synaptic membranes. Biochemistry 15:1425–34
   [Google Scholar]
10. 10. 

    Taylor P, Radić Z. 1994. The cholinesterases: from genes to proteins. Annu. Rev. Pharmacol. Toxicol. 34:281–320
    [Google Scholar]
11. 11. 

    Rachinsky TL, Camp S, Li Y, Ekström TJ, Newton M, Taylor P 1990. Molecular cloning of murine acetylcholinesterase: tissue distribution of alternatively spliced mRNA species. Neuron 5:317–27
    [Google Scholar]
12. 12. 

    Maulet Y, Camp S, Gibney G, Rachinsky TL, Ekström TJ, Taylor P 1990. Single gene encodes glycophospholipid and asymmetric acetylcholinesterase forms: Alternative coding exons contain inverted repeat sequences. Neuron 4:289–301
    [Google Scholar]
13. 13. 

    Li Y, Camp S, Rachinsky TL, Getman D, Taylor P 1991. Gene structure of mammalian acetylcholinesterase: Alternative exons dictate tissue specific expression. J. Biol. Chem. 266:23083–90
    [Google Scholar]
14. 14. 

    Camp S, De Jaco A, Zhang L, Marquez M, de la Torre B, Taylor P 2008. Acetylcholinesterase expression in muscle is specifically controlled by a promoter-selective enhancesome in the first intron. J. Neurosci. 28:102459–70
    [Google Scholar]
15. 15. 

    Taylor P, Jacobs NM. 1974. Interaction between bisquaternary ammonium ligands and acetylcholinesterase: complex formation studies by fluorescence quenching. Mol. Pharmacol. 10:93–107
    [Google Scholar]
16. 16. 

    Taylor P, Lappi S. 1975. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 14:1989–97
    [Google Scholar]
17. 17. 

    Schumacher M, Camp S, Maulet Y, Newton M, MacPhee-Quigley K et al. 1986. Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature 319:407–9
    [Google Scholar]
18. 18. 

    Sussman JL, Harel M, Frolow F, Oefner C, Goldman A et al. 1991. Atomic structure of acetylcholinesterase from Torpedo californica: a prototype acetylcholine binding protein. Science 253:872–79
    [Google Scholar]
19. 19. 

    Cygler M, Schrig JD, Sussman JL, Harel M, Silman I et al. 1993. Relationship between sequence and three-dimensional structures of a large family of esterases, lipases, and related proteins. Protein Sci 2:366–82
    [Google Scholar]
20. 20. 

    Kalow WM. 1993. Pharmacogenetics: its biological roots and the medical challenge. Clin. Pharmacol. Ther. 54:235–46
    [Google Scholar]
21. 21. 

    Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A et al. 2000. Postnatal development delay and super-sensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Exp. Ther. 293:892–902
    [Google Scholar]
22. 22. 

    Lewis WG, Green LG, Grynszpan F, Radić Z, Carlier PR et al. 2002. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. Engl. 41:1053–57
    [Google Scholar]
23. 23. 

    Manetsch R, Krasiński A, Radić Z, Raushel J, Taylor P et al. 2004. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 126:12809–18
    [Google Scholar]
24. 24. 

    Lee J-H, Jeong S-K, Kim BC, Park KW, Dash A 2015. Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance. Acta Neurol. Scand. 131:259–67
    [Google Scholar]
25. 25. 

    Kovarik Z, Kalisiak J, Maček Hrvat N, Katalinić M, Zorbaz T et al. 2019. Reversal of tabun toxicity enabled by a triazole-annulated oxime library—reactivation of acetylcholinesterase. Chem. Eur. J. 25:4100–14
    [Google Scholar]
26. 26. 

    Edery H, Geyer M, Taylor P, Berman HA 1986. Target sites for anticholinesterases on the ventral surface of the medulla oblongata: hypotension elicited by organophosphorus agents. J. Auton. Pharmacol. 6:195–209
    [Google Scholar]
27. 27. 

    Radić Z, Sit RK, Kovarik Z, Berend S, Garcia E et al. 2012. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J. Biol. Chem. 287:11798–809
    [Google Scholar]
28. 28. 

    Sit RK, Kovarik Z, Maček Hrvat N, Žunec S, Green C et al. 2018. Pharmacology, pharmacokinetics and tissue disposition of zwitterionic hydroxyiminoacetamido alkylamines as reactivating antidotes for organophosphate exposure. J. Pharmacol. Exp. Ther. 367:363–72
    [Google Scholar]
29. 29. 

    Rosenberg YJ, Mao L, Jiang X, Lees J, Zhang L et al. 2107. Post-exposure treatment with the oxime RS194B rapidly reverses early and advanced symptoms in macaques exposed to sarin vapor. Chem. Biol. Interact. 274:50–57
    [Google Scholar]
30. 30. 

    Rosenberg YJ, Wang J, Ooms T, Rajendran N, Mao L et al. 2018. Post-exposure treatment rapidly reactivates and reverses advanced symptoms of lethal paraoxon exposure in macaques. Toxicol. Lett. 293:229–34
    [Google Scholar]
31. 31. 

    Taylor P, Shyong Y-J, Momper J, Hou W, Camacho-Hernandez GA et al. 2019. Assessment of ionizable, zwitterionic oximes as reactivating antidotal agents for organophosphate exposure. Chem. Biol. Interact. 308:194–97
    [Google Scholar]
32. 32. 

    Changeux J-P, Edelstein SJ. 2005. Nicotinic Acetylcholine Receptors New York: Odile Jacob
33. 33. 

    Karlin A. 2002. Emerging structures of nicotinic acetylcholine receptors. Nat. Rev. Neurosci. 3:102–14
    [Google Scholar]
34. 34. 

    Monod J, Wyman J, Changeux J-P 1965. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:88–118
    [Google Scholar]
35. 35. 

    Unwin N. 2005. Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J. Mol. Biol. 346:967–89
    [Google Scholar]
36. 36. 

    Katz B, Thesleff S. 1957. A study of desensitization produced by acetylcholine at the motor endplate. J. Physiol. 138:63–80
    [Google Scholar]
37. 37. 

    Weiland G, Georgia B, Lappi S, Chignell CF, Taylor P 1977. Kinetics of agonist-mediated transitions in state of the cholinergic receptor. J. Biol. Chem. 257:7648–56
    [Google Scholar]
38. 38. 

    Sine SM, Taylor P. 1980. The relationship between agonist occupation and the permeability response of the cholinergic receptor revealed by bound cobra α-toxin. J. Biol. Chem. 255:10144–56
    [Google Scholar]
39. 39. 

    Sine SM, Taylor P. 1981. Relationship between reversible antagonist occupancy and the functional capacity of the acetylcholine receptor. J. Biol. Chem. 256:6692–99
    [Google Scholar]
40. 40. 

    Kreienkamp HJ, Maeda RK, Sine SM, Taylor P 1995. Intersubunit contacts governing assembly of nicotinic acetylcholine receptors. Neuron 14:635–44
    [Google Scholar]
41. 41. 

    Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J et al. 2001. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269–76
    [Google Scholar]
42. 42. 

    Celie PHN, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK 2004. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studies in AChBP crystal structures. Neuron 41:907–14
    [Google Scholar]
43. 43. 

    Hansen SB, Talley TT, Radić Z, Taylor P 2004. Structure and recognition characteristics of an acetylcholine-binding protein from Aplysia californica. J. Biol. . Chem 279:24197–202
    [Google Scholar]
44. 44. 

    Grimster NP, Stump B, Fotsing JR, Weide T, Talley TT et al. 2012. Generation of candidate ligands for nicotinic acetylcholine receptors via in situ click-chemistry with a soluble acetylcholine binding protein template. J. Am. Chem. Soc. 134:6732–40
    [Google Scholar]
45. 45. 

    Walsh RM Jr, Roh S-H, Gharpure A, Morales-Perez CL, Teng J, Hibbs RE. 2018. Structural principles of distinct assembles of the human α4β2 nicotinic receptor. Nature 557:261–65
    [Google Scholar]
46. 46. 

    Gharpure A, Teng J, Zhuang Y, Noviello CM, Walsh RM Jr et al. 2019. Agonist selectivity and ion permeability in the α3β4 ganglionic nicotinic receptor. Neuron 104:501–11.e6
    [Google Scholar]
47. 47. 

    Bertrand D, Lee C-HL, Flood D, Marger F, Donnelly-Roberts D 2015. Therapeutic potential of α7 nicotinic acetylcholine receptors. Pharmacol. Rev. 67:1025–73
    [Google Scholar]
48. 48. 

    Kaczanowska K, Camacho-Hernandez GA, Bendicks L, Kohs L, Cornejo-Bravo JM et al. 2017. Substituted 2-aminopyrimidines selective for α7-nicotinic acetylcholine receptor activation and association with acetylcholine binding proteins. J. Am. Chem. Soc. 139:3676–84
    [Google Scholar]
49. 49. 

    Camacho-Hernandez GA, Stokes C, Duggan BM, Kaczanowska K, Brandao-Araisa S et al. 2019. Synthesis, pharmacological characterization, and structure-activity relationships of noncanonical selective agonists for the α7 nAChRs. J. Med. Chem. 62:10376–90
    [Google Scholar]
50. 50. 

    Camacho-Hernandez GA, Taylor P. 2020. Lessons from nature: structural studies and drug design driven by a homologous surrogate from invertebrates, AChBP. Neuropharmacology 2020:108108
    [Google Scholar]
51. 51. 

    Comoletti D, Flynn R, Jennings LL, Chubykin A, Matsumura T et al. 2003. Characterization of the interaction of a recombinant soluble neuroligin-1 with neurexin-1β. J. Biol. Chem. 278:50497–505
    [Google Scholar]
52. 52. 

    Boucard AA, Chubykin AM, Comoletti D, Taylor P, Südhof TC 2005. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to α- and β-neurexins. Neuron 48:226–36
    [Google Scholar]
53. 53. 

    Comoletti D, Grishaev A, Whitten AE, Tsigelny I, Taylor P, Trewhella J 2007. Synaptic arrangement of neuroligin/β-neurexin complex revealed by X-ray and neutron scattering. Structure 15:693–705
    [Google Scholar]
54. 54. 

    Miller MT, Mileni M, Comoletti D, Stevens RC, Harel M, Taylor P 2011. The crystal structure of the α-neurexin-1 extracellular region reveals a hinge point for mediating synaptic adhesion and function. Structure 19:767–78
    [Google Scholar]
55. 55. 

    Bourne Y, Chatonnet A, Marchot P 2019. Alpha-beta-hydrolase-fold proteins: a structural motif with multiple variations and functions Abstract presented at the 16th International Symposium on Cholinergic Mechanisms Rehovot, Israel: Dec 8–13
56. 56. 

    Changeux J-P. 2010. Allosteric receptors from the electric organ to cognition. Annu. Rev. Pharmacol. Toxicol. 50:1–38
    [Google Scholar]
57. 57. 

    Burgen ASV. 2000. Targets of drug action. Annu. Rev. Pharmacol. Toxicol. 40:1–16
    [Google Scholar]
58. 58. 

    Brunton LL, Hilal-Dandan R, Knollmann BC 2018. Goodman and Gilman's Pharmacological Basis of Therapeutics New York: McGraw-Hill. , 13th ed..
59. 59. 

    Brooke R. 1934. The Complete Poems of Rupert Brooke London: Sidgwick & Jackson
60. 60. 

    Taylor P. 1991. The cholinesterases. J. Biol. Chem. 266:4025–28
    [Google Scholar]
61. 61. 

    Taylor P, Brown JH. 2006. Acetylcholine. Basic Neurochemistry: Molecular, Cellular and Medical Aspects GJ Siegel, BW Agranoff, RW Albers, PB Molinoff pp.185–209 New York: Raven Press Limited. , 5th ed..
    [Google Scholar]
62. 62. 

    Gorecki L, Gerlits O, Kong X, Cheng X, Blumenthal DK et al. 2020. Rational design, synthesis, and evaluation of uncharged, “smart” bis-oxime antidotes of organophosphate-inhibited human acetylcholinesterase. J. Biol. Chem. 295:134079–92 2020. J. Biol. Chem 295:196784
    [Google Scholar]